Clinical Risk Factors Associated with Nausea and Vomiting in Patients Receiving Extended-release Oxycodone

DOI 1 Citations 9 References
  • Ariyoshi Kimiyo
    Department of Hospital Pharmacy, Nagasaki University Hospital
  • Kitahara Takashi
    Department of Hospital Pharmacy, Nagasaki University Hospital
  • Ryu Emi
    Department of Hospital Pharmacy, Nagasaki University Hospital
  • Takada Masafumi
    Department of Anesthesiology, Nagasaki University Hospital
  • Munakata Chie
    Department of Hospital Pharmacy, Nagasaki University Hospital
  • Nose Seiichi
    Department of Hospital Pharmacy, Nagasaki University Hospital
  • Miyanaga Kei
    Department of Hospital Pharmacy, Nagasaki University Hospital
  • Higuchi Norihide
    Department of Hospital Pharmacy, Nagasaki University Hospital
  • Hojo Minoru
    Department of Anesthesiology, Nagasaki University Hospital
  • Sasaki Hitoshi
    Department of Hospital Pharmacy, Nagasaki University Hospital

Bibliographic Information

Other Title
  • 徐放性オキシコドン導入時の嘔気・嘔吐における患者リスク因子に関する検討

Search this article

Abstract

In Japan, cancer has been the leading cause of death since the 1980s. 70-80％ of cancer patients need cancer pain treatment. Currently oxycodone has a central role in cancer pain treatment, and its consumption is increasing every year.However, nausea and vomiting are produced at the start of oxycodone dosing that often leads to discontinuation of treatment.<br>In this study, we retrospectively investigated the medical records of 112 patients who had cancer in order to examine risk factors related to nausea and vomiting at the start of oral oxycodone dosing. As a result, the incidence of nausea and vomiting was 25％ at the start of oral oxycodone dosing. Multiple logistic regression analysis showed that there were significant differences for young people under the age of 50 (odds ratio = 5.32, 95％ CI = 1.54-18.4, P = 0.008), nonsmokers (odds ratio = 8.39, 95％ CI = 1.47-48.0, P = 0.017) and gastrointestinal primary cancer (odds ratio = 4.14, 95％ CI = 1.32-13.0, P = 0.015).<br>We revealed risk factors at the start of oral oxycodone dosing. This result provides useful knowledge on maintaining the continuity of cancer pain treatment and QOL of patients.

Journal

Citations (1)*help

See more

References(9)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top